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Background: Growth hormone secretagogues (GHS), among other factors, regulate the release of GH. The
biological activity of the secretagogue peptide A233 as a promoter of growth and innate immunity in
teleost ﬁsh has previously been demonstrated, but its role in the immune system of mammals is not well
understood.
Methods: The effect of the peptide was investigated in J774A.2 macrophage cells using a comparative
proteomics approach after 6 and 12 h of peptide stimulation.
Results: The functional analysis of differentially modulated proteins showed that A233 peptide treatment
appears to promote activation and ROS-dependent cytotoxic functions in macrophages and enhanced
expression of antiviral protein complexes such as MAVS. In accordance with this hypothesis, we found
that A233 treatment enhanced superoxide anion production and the IFN-γ level in J774A.2 cells and
mouse splenocytes, respectively, and reduced viral load in a dengue virus mouse model of infection.
Conclusions: The growth hormone secretagogue A233 peptide promotes activation of ROS-dependent
cytotoxic functions and exerts immunomodulatory effects that enable an antiviral state in a dengue virus
mouse model.
General Signiﬁcance: The increase of IFN-γ level and the differential modulation of antiviral proteins by
the A233 peptide suggest that the molecule could activate an innate immune response with a possible
further impact in the treatment of acute and chronic diseases.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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trada),1. Introduction
Growth hormone secretagogues (GHS) such as ghrelin induce
an array of effects in different types of organisms [1]. The A233
decapeptide is a novel synthetic GHS obtained from a massive
docking experiment performed against a molecular model of the
GHS receptor. So far, studies have demonstrated an impact of
peptide treatment on growth, immune system function, and an-
tioxidant defense in tilapia ﬁsh [2].
The role of ghrelin in immune cell activation includes thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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naling pathways [3]. For example, murine RAW 264.7 macro-
phages express both ghrelin and GHS receptors. Treatment of
these cells with exogenous ghrelin decreases LPS-dependent NF-
κB activation and subsequent IL-1β and TNF-α production (pro-
inﬂammatory cytokines), while it increases IL10 (anti-in-
ﬂammatory cytokine) levels through the p38MAPK pathway [4].
GHS also stimulates oxidized LDL uptake by macrophages and
PPAR-γ signaling, both being functions associated with the pa-
thogenesis of cardiovascular diseases such as atherosclerosis [5,6].
Macrophage activation is a complex process that involves sig-
niﬁcant changes in metabolism and gene expression [7]. Two main
classiﬁcations exist for activated macrophages: M1 (classically
activated) and M2 (alternatively activated). This classiﬁcation re-
presents extremes of functional polarization [8]. M1 polarization
of macrophages occurs in the presence of interferon-γ (IFN-γ) and
lipopolysaccharide (LPS), whereas exposure to interleukins IL-4
and IL-13 induces M2 polarization. Classically activated macro-
phages display strong anti-pathogen and antitumor activity, in-
ducing an increase of pro-inﬂammatory cytokines, reactive oxygen
species (ROS) and reactive nitrogen species (RNS). Alternatively
activated macrophages function in tissue remodeling, tumor pro-
gression, immunoregulation, inﬂammation reduction, and parasite
elimination [9].
The evidence of immune system stimulation by the A233
peptide in teleost ﬁsh prompted us to investigate this process in
mouse macrophages to obtain a better understanding of the effect
at the molecular level. This work explores the proteome of J774A.2
mouse macrophage cells stimulated by treatment with A233 for
6 or 12 h. Differentially modulated proteins were found by quan-
titative comparison using 4-plex iTRAQ derivatization. The func-
tional analysis of the differentially modulated proteins in the
context of macrophage activation suggested that peptide treat-
ment induces M1 polarization. To investigate these events, we
measured the levels of •−O2 (superoxide anion) and IFN-γ, two key
players in classical macrophage activation. A signiﬁcant increase of
both molecules was found, which reﬂects an enhancement in ROS-
dependent cytotoxicity and the induction of an antiviral state in
treated macrophages and splenocytes, respectively.
Data obtained by our proteomics study revealed the up-reg-
ulation of proteins related to inﬂammation and antiviral activity,
such as mitochondrial antiviral signaling protein (MAVS), which
plays an important role in antiviral innate immunity as well as cell
death. Given the importance of these ﬁndings, the antiviral re-
sponse induced by the A233 peptide was studied in a mouse
model of intracranial dengue virus infection. To our knowledge,
this is the ﬁrst time that antiviral activity in vivo produced by a
secretagogue growth hormone has been reported.2. Materials and methods
2.1. Peptide synthesis
The decapeptide A233 (GKFDLSPEHQ), with a lactam bond
between side chain functional groups of Lys2 and Asp4, was
manually synthesized on Fmoc-AM-PEG-PS resin (substitution
level: 0.18 mmol/g) using the Fmoc/tBu strategy. All side-chains
were protected with TFA-labile groups and the side-chain pro-
tections used for Lys and Asp were allyloxycarbonyl (Alloc) and
allyl (All), respectively. Removal of the Fmoc group was carried out
with 20% piperidine in DMF and the Fmoc-amino acids were
coupled using DIC/HOBt activation. Once the complete peptide
sequence had been assembled, and maintaining the Fmoc-Nα-
protection, the Alloc-All groups were removed by treatment with
phenylsilane and tetrakistriphenylphosphine palladium (0). Thelactam bond was obtained by treatment of the peptide-resin with
PyBOP/DIEA in DMF. Side-chain deprotection and cleavage from
the resin were carried out with TFA-H2O-TIS (95:2.5:2.5 v/v). The
peptide was puriﬁed by reversed-phase high performance liquid
chromatography (RP-HPLC). The A233 peptide was obtained with
purity higher than 95%, as estimated by analytical RP-HPLC. The
identity of the A233 was veriﬁed by ESI-MS analysis. The experi-
mental (1137.58 Da) and calculated (1137.56 Da) monoisotopic
molecular mass agreed, considering the formation of the lactam
bond previously described. The ESI-MS/MS spectrum of the dou-
bly-charged ion of A233 peptide (m/z 569.79, 2þ) was acquired to
obtain structural evidence of the lactam bond formation between
Lys2 and Asp4 from the backbone and internal fragment ions. The
positive control GHRP-6 (Lipotec, Barcelona, Spain) and its an-
tagonist [D-Lys3]-GHRP-6 (Sigma), both lyophilized, were recon-
stituted in PBS for use in in vitro and in vivo assays.
2.2. Reverse phase chromatography.
A233 peptide was analyzed on an AKTA 100 (GE Healthcare,
USA) HPLC system. Analytical analysis was accomplished in a re-
verse-phase (RP) C18 analytical column (4.6  150 mm, 5 μm)
(Vydac, USA). To assess the peptide purity, the column was equi-
librated in 95% solution A, then a linear gradient from 5% to 60%
solution B, over 35 min, was used keeping a ﬂow rate of 0.8 mL/
min. The solutions A and B used in the puriﬁcation were 0.1% of
TFA in water, and 0.05% of TFA in pure acetonitrile, respectively.
Chromatograms were acquired at 226 nm, using the UNICORN 4.11
(GE Healthcare, USA) software package for data processing of the
RP-HPLC chromatograms. The semipreparative puriﬁcation was
performed on a LaChrom (Merck-Hitachi, Germany) HPLC system.
Separation was achieved using an RP C18 preparative column
(Vydac, 25  250 mm, 25 μm). A linear gradient from 15% to 45%
of solvent B over 50 min and a ﬂow rate of 5 mL/min were used.
Solvents A and B are composed of 0.1% (v/v) of TFA in water and
0.05% (v/v) of TFA in acetonitrile, respectively. Detection was
monitored at 226 nm.
2.3. Mass spectrometric analysis.
ESI-MS analysis was performed in a hybrid quadrupole-time-
of-ﬂight (QTOF-2™) tandem mass spectrometer (Waters, Milford,
MA, USA) equipped with a Z-nanospray ion source. Capillary and
cone voltages were set to 900 and 35 V, respectively. A 5 μL aliquot
of the peptide puriﬁed by RP-HPLC was loaded into a glass capil-
lary coated with conductive material (New Objective, Woburn,
MA, USA). The tip of the capillary was gently broken, while slightly
pressurized with nitrogen, in order to get a stable spray during the
measurement. The TOF and MCP were operated at 2.2 kV and 9 kV,
respectively. The source was heated at 90 °C. The doubly-charged
ion of the A233 peptide (m/z 569.79, 2þ) was selected in the ﬁrst
quadrupole and fragmented inside the collision cell operated at
collision energy of 35 eV to obtain an MS/MS spectrum with
structural information. Ultrapure Argon (Gases Industriales, Cuba)
was used as a collision gas. Data acquisition and processing were
performed with the MassLynx (v. 4.0) software package (Waters,
USA).
2.4. Growth conditions for J774.2 cells
The J774A.2 cell line was obtained from ECACC (85011428
Sigma). The cells were cultured as monolayers in Dulbecco's
Modiﬁed Essential Medium (DMEM) F12 supplemented with 20%
fetal bovine serum (FBS), 100 mg/mL penicillin/streptomycin, and
2 mM L-glutamine (Mediatech, Inc., Herndon, VA) at 37 °C in a
humidiﬁed atmosphere of 5% CO2. The cultured cells were grown
R. Martínez et al. / Biochemistry and Biophysics Reports 5 (2016) 379–387 381to 70–80% conﬂuence in 75 cm2 ﬂasks for preparation of samples
that were used in further analyses.
2.5. Superoxide production by J774.2 cells
Superoxide anion production was measured in J774.2 cells by
the reduction of nitro blue tetrazolium (NBT; Sigma, USA) fol-
lowing the procedure described by Yada et al. [10].
2.6. IFN-γ production in mouse splenocytes
Mouse splenocytes were obtained in aseptic conditions, and
erythrocytes were lysed by adding 0.83% NH4Cl solution. Cells
were washed twice with PBS containing 2% FBS (PAA Laboratories,
ON, Canada) and resuspended at 2  106 cells/mL in RPMI 1640
medium (Sigma Aldrich, USA) supplemented with 100 U/mL pe-
nicillin, 100 μg/mL streptomycin (Gibco, UK), 2 mM glutamine
(Gibco), 5  105 M 2-mercaptoethanol (Sigma, USA) and 5% FBS.
Finally, 2.5  105 cells per well were cultured in 96-well round-
bottom plates with the peptides at a ﬁnal concentration of
10 μg/mL. Concanavalin-A (Sigma) was used as a positive control.
In all experiments, three wells were plated for each antigen. After
4 days of culture, culture supernatants were collected and stored
at 20 °C. IFN-γ was determined by ELISA (as recommended by
Mabtech) in duplicate samples from culture supernatants.
2.7. Reduction and S-alkylation
Tubes containing proteins from each of the three experimental
conditions (control at 0 h, and 6 h or 12 h of A233 treatment) re-
ceived 45 mL of 50 mM Hepes, 2 M GuCl, pH 8.5 and the mixtures
were reduced by adding dithiothreitol (DTT) to a ﬁnal concentra-
tion of 10 mM and incubating the tubes for 4 h at 37 °C. The free
thiol groups were alkylated by adding iodoacetamide to a ﬁnal
concentration of 20 mM, and allowing the reactions to proceed (in
darkness) for an additional 30 min at room temperature.
2.8. Proteolytic digest
Hepes, pH 8.5 (50 mM) was added to 100 mL ﬁnal volume, and
proteins were digested with Lysyl-endopeptidase (Wako, Japan)
using an enzyme:substrate ratio of 1:100 for 4 h at 37 °C. After
digestion, the peptide mixture was diluted with water up to
0.5 mol/L guanidium hydrochloride. Sequencing grade trypsin
(Promega, USA) was added to a concentration of 1:100 (enzyme:
substrate), and the reaction proceeded for 16 h at 37 °C.
2.8.1. iTRAQ modiﬁcation
Eighty μg of protein digest was dried and re-suspended in
30 μL of 50 mM Hepes, pH 8.5, for labeling using the iTRAQ Re-
agents Four-plex Kit (Applied Biosystems, USA), according to the
manufacturer's protocol. Brieﬂy, each peptide solution was labeled
at room temperature for 1 h with one iTRAQ reagent vial (mass tag
114, 115 or 117) previously reconstituted with 70 μL of ethanol. The
differential protein expression proﬁles of J774A.2 in the three
conditions were analyzed in duplicate: 0 h control sample (114)
and 6 h (115) and 12 h (117) of the A233 treatment. Samples with
the same amount of protein, labeled with 114, 115 and 117 iTRAQ
reagents, respectively, were combined into a single fraction, and
the labeling reaction was stopped by evaporation in a Speed Vac
(Savant, USA). The samples were desalted using RP-cartridges (RP
C8, SPE Sep-Pak Light, Waters, USA) and eluted in 3 mL of 80%
acetonitrile. The ﬁnal solutions were dried by evaporation in a
Speed Vac.2.8.2. Fractionation of the iTRAQ-labeled peptide mixture
For pI-based peptide separation, a 3100 OFFGEL Fractionator
(Agilent Technologies, Germany) was used with a 12-well set-up.
Prior to electrofocusing, samples were desalted using a Sep-Pak
C18 cartridge (Waters, USA),dried and diluted to a ﬁnal volume of
3.6 mL using OFFGEL peptide sample solution. The IPG gel strips
(13 cm-long) with a 3–10 linear pH range (GE Healthcare, Ger-
many) were rehydrated for 15 min with the Peptide IPG Strip Re-
hydradation Solution according to the manufacturer's instructions.
Then, 150 μL of sample was loaded into each well. Electrofocusing
of the peptides was performed at 20 °C and 50 μA until the 20 kVh
level was reached. All fractions were desalted using Stage-tips
(Thermo, USA) and evaporated by centrifugation under vacuum
and maintained at 20 °C. Just prior to nano-LC, the fractions
were resuspended in 20 μL H2O with 0.1% (v/v) triﬂuoroacetic acid.
2.8.3. LC-MS/MS analysis of iTRAQ-labeled peptides
The labeled peptides were dissolved in 0.1% formic acid solu-
tion and delivered into an RP nano-EASY column (75 μm inner
diameter  100 mm length, 3 μm particle size, C18-A2 resin;
(Thermo Scientiﬁc, USA) previously equilibrated in 5% of solution A
(0.1% formic acid in water). The retained peptides were eluted
using a linear gradient by increasing the content of solution B (0.1%
of formic acid in acetonitrile) in the mobile phase from 5% to 45%
over 90 min, at 200 nL/min. The eluated peptides were analyzed
in an LTQ-Orbitrap Velos MS (Thermo Fisher Scientiﬁc, USA). MS
data were acquired via data-dependent acquisition, mode by se-
lecting the twenty top-most intense signals for an automatic MS/
MS analysis. For the MS spectra, the resolution was 60,000
(FWHM) at m/z 400, and the m/z range was set from 350 to 1650.
Fragmentation of peptides was achieved by HCD (higher energy
collisional dissociation) activation with a resolution of 7500
(FWHM), isolation width of 2m/z units, and ﬁrst mass atm/z¼100.
Normalized collision energies (NCEs) were set to 35%.
2.8.4. Data analysis
The Mascot (version 2.3.02) search engine and UniProtKB/
Swiss-Prot database (11-2011, 533 049 entries) were used for
peptide and protein identiﬁcation. The search space was reduced
down to 16 409 entries after applying a taxonomy ﬁlter by con-
sidering only Mus muculus derived proteins. Mascot tolerance
parameters were set to 10 ppm and 0.2 Da for precursor mass and
product ion, respectively. Other parameters used were trypsin
digestion with up to two missed cleavages and a ﬁxed modiﬁca-
tion of cysteine residues (carbamidomethylation). Oxidation of
methionine to sulfoxide and iTRAQ 4-plex peptide labels were
used as variable modiﬁcations. A reverse decoy database was
generated and joined to the target database for false discovery
calculations (o 1% FDR at the peptide level was accepted). Pep-
tides below the identity threshold (score 23) were not considered
for analysis.
The data was analyzed using the corresponding statistical tools
from the MASCOT Distiller software package (version 2.5.1.0). The
statistical processing includes a test of normality for the dis-
tribution of peptide fold-change values. Once it has been estab-
lished that the data is normally distributed then the geometric
mean of these values is compared to the unit using the Student's t-
test (p¼0.05). The MASCOT Distiller software reports as regulated
proteins those with fold-change values that are statistically dif-
ferent from unity. If the protein fold-change values did not set to a
normal distribution, or the quantiﬁcation is based in one or two
peptides, the p value was calculated based on the analysis of the
individual peptide(s) detected in an OFFGEL fraction that has a
normal distribution. The fold changes calculated for the individual
proteins in the experimental conditions are expressed respect to
the intensity of the ion at m/z 114 used as control of the
R. Martínez et al. / Biochemistry and Biophysics Reports 5 (2016) 379–387382experiment (0 h).
2.9. Mouse experiments and viral load detection in brain
Female BALB/c (Bc, H-2d) mice (aged 6–8 weeks) were pur-
chased from CENPALAB (Havana, Cuba) and housed in appropriate
animal care facilities during the experimental period. Mouse ex-
periments were carried out in strict accordance with the re-
commendations in the Guide for the Care and Use of Laboratory
Animals of the Center for Genetic Engineering and Biotechnology
(CIGB), Cuba. The protocols were approved by the CIGB Committee
on Ethics for Animal Experiments.
Two groups of eight mice were injected intraperitoneally on
days 0, 1, 3, 4, 6 and 7 with 10 mg of peptide A233 per animal or
PBS (control) without adjuvant in a ﬁnal volume of 100 μL. A third
group was injected with the [D-Lys3]-GHRP6 antagonist peptide
using the same schedule. As a positive control for the challenge
with dengue virus (DENV), a fourth group of animals was in-
oculated with 105 plaque-forming units (pfu) of an infectious
preparation of DENV-3 (H87 strain, 27 passages in mice) on day 0.
On day 8, animals were challenged with 50 LD50 of neuroa-
dapted DENV-3 H87 by intracranial injection. Seven days after
challenge, mice were euthanized to measure the viral load in brain
as previously reported [11]. Brains were harvested and aseptically
homogenized with 1 mL of PBS supplemented with 2% FBS,
100 U/mL penicillin and 100 μg/mL streptomycin. The suspensions
were centrifuged for 10 min at 8000g, and supernatants were
collected and stored at 80 °C.
For viral load measurement, 5105 Vero cells/well were cul-
tured for 24 h in six-well plates with MEM (Sigma Aldrich) sup-
plemented with 100 U/mL penicillin, 100 μg/mL streptomycin,
2 mM glutamine, 1 mM sodium pyruvate (Gibco, UK), and 2% FBS.
Cells were infected with different dilutions of the infected brain
supernatants in MEM medium supplemented with 1% FBS. After
infection (4 h at 37 °C and 5% CO2), the overlay mediumwas added
(3% carboxymethylcellulose), and the plates were incubated at
37 °C and 5% CO2 for 4 days. Infected cells were visualized by
immunofocusing. Brieﬂy, the cells were ﬁxed with 4% formalin for
1 h, washed twice with PBS, and then incubated in PBS-1% Triton
X-100 for 15 min. After permeabilization, blocking buffer (PBS
supplemented with 10% FBS) was added to each well for 30 min at
room temperature. After blocking, the cells were incubated with
monoclonal antibody 4G2 (which recognizes the envelope protein
of DENV) at 1 mg/mL (in PBS and 1% FBS) for 1 h at room tem-
perature. After two washes with PBS, polyclonal anti-mouse IgG-
HRP (Sigma Aldrich, USA) was added at a dilution of 1:2000 (in
PBS and 1% FBS) and incubated for 1 h at room temperature. The
cells were then washed twice with 50 mM Tris, pH 7.4, and a
substrate solution of 0.5 mg/mL diaminobenzidine, 0.2 mg/mL
CaCl2, and 9 mg/mL NaCl in 50 mM Tris, pH 7.4, was added to each
well. The plates were left on a shaker for 30 min until clear foci
were visible for subsequent counting. The detection limit was
10 pfu/mL.
2.10. Statistical analysis
For statistical analysis, GraphPad Prism version 5.0 for Win-
dows (GraphPad Software, San Diego, CA) was used. The normal
distribution of data was analyzed with D'Agostino Pearson's test
and the variance homogeneity with Bartlett's test. When normal
or transformed data showed a normal distribution, a parametric
test was performed; otherwise data were analyzed with a non-
parametric test. The parametric analysis of more than two groups
was performed by a one-way analysis of variance, using Newman–
Keuls post-test. The non-parametric analysis of more than two
groups was performed using Kruskal–Wallis and Dunn multiplecomparison test. In all cases *: po0.05; **: po0.01; ***: po0.001.
2.11. Bioinformatics analysis
The functional analysis of the differentially modulated proteins
was performed in the context of classical macrophage activation.
First, the function of the differentially modulated proteins was
extracted from UniProtKB database [12] and the scientiﬁc litera-
ture. Information from the literature concerning macrophage ac-
tivation and its relation with the differentially modulated proteins
was explored with the information retrieval and text mining tool
GoPubMed [13]. Next, an enrichment analysis of the differentially
modulated proteins, at both 6 and 12 h and at each time sepa-
rately, was performed based on the following biological annota-
tions: GO biological process, GO molecular function, KEGG path-
way, transcription factor binding site (TFBS), and mammalian
phenotype ontology (MPO) [14]. GeneCodis [15] was used for GO
annotations and KEGG pathway enrichment analyses, InnateDB
[16] for TFBS enrichment analysis, and NetVenn [17] for MPO en-
richment analysis. Default parameters were kept and the sig-
niﬁcance level was set at po0.05.3. Results
The A233 peptide is a novel synthetic GHS that enhances both
growth and the innate immune system in teleost ﬁsh [2]. Here we
analyzed the proteome of the J774.2 macrophage cell line, stimu-
lated with the peptide for 6 and 12 h. Limits for the fold changes
were ﬁxed in 0.60 and 1.5 order to identify down- and up-regu-
lated expressed proteins. With this analysis we identiﬁed a total of
1384 proteins using 1% of false discovery rate. In Table 1, (Sup-
plementary Material) the differentially expressed proteins are
shadowed in gray. Three hundred thirty six proteins of which were
differentially regulated after 6 h of treatment (between 78 and 258
proteins down- and up-regulated). After 12 h of treatment 280
proteins were differentially expressed (between 56 and 224 pro-
teins down- and up-regulated).
The modulated proteins that might be relevant for the effect of
A233 on macrophages after 6 and 12 h are summarized in Table 1.
At six hours, 14 and 9 of these proteins were up- and down-
regulated, respectively and with p values lower than 0.05. At 12 h
17 and 8 proteins were up- and down regulated, respectively. In
Table 1 there are other proteins with fold changes that exceed
these thresholds and could be potentially considered as differen-
tially expressed but MASCOT did not calculate a p value either
because the quantiﬁcation is based on one or two peptides or the
fold changes of the peptides used for the quantiﬁcation did not
have a normal distribution.
The GO biological process and KEGG pathway enrichment
analyses of the differentially modulated proteins at both time
points show the down-regulation of fatty-acid beta oxidation and
the up-regulation of DNA repair and the inﬂammatory response
(Fig. 1, Supplemental Table 2). These analyses at each time point
separately also revealed the up-regulation of glycolysis after 6 h of
treatment and the citrate cycle after 12 h, whereas they point to a
down-regulation of electron transport chain at 6 h post-treatment
(Fig. 1, Supplemental Table 2). Other biological processes or
pathways modulated by the peptide treatment were: oxidation-
reduction, response to hydrogen peroxide, activation of cysteine-
type endopeptidase activity involved in apoptotic processes, and
positive regulation of TNF production (Fig. 1, Supplemental Ta-
ble 2). These signiﬁcant enrichments suggest that peptide treat-
ment impacts glucose and fatty acid catabolism, the oxidation-
reduction process, DNA repair, apoptosis, and inﬂammation. Based
on these ﬁndings, we further investigated the effect of A233
Table 1
Differentially modulated proteins at 6 and/or 12 h A233 peptide treatment that might be relevant for the effect on macrophages.
UniProt Acc Gene Name Protein name Fold-Change treated Fold-Change treated
6 hf 12 hf
Apoptotic process
P63038/ Hspd1 60 kDa heat shock protein, mitochondrial 0.729 c 0.52 (F7) d
p¼ — p¼ 0.05CH60_MOUSE
DNA damage response and repair
Q9D1M4/ Eef1e1 Eukaryotic translation elongation factor 1 epsilon-1 1.903 (F6) 1.757 (F7)d
MCA3_MOUSE p¼0.0328 p¼0.0262
P52479/ Usp10 Ubiquitin carboxyl-terminal hydrolase 10 1.881(F6) * d, e 1.84 (F6)* d, e
UBP10_MOUSE p¼0.0585 p¼0.0655
Q8R2Y9/ Nabp1 SOSS complex subunit B1 2.082 c 2.196 a
SOSB1_MOUSE p¼ — p¼ 0.008648
Q8BGW5/ Ruvbl2 RuvB-like 2 1.505* e 1.686 a
p¼0.07101 p¼0.01872RUVB2_MOUSE
Q9WTM5/ Ash2l Set1/Ash2 histone methyltransferase complex subunit ASH2 2.5 b 2.33 b
ASH2L_MOUSE p¼N/A p¼N/A
Inﬂammation and anti-viral response
Q60875/ Arhgef2 Rho guanine nucleotide exchange factor 2 1.783 b 1.952 b
ARHG2_MOUSE p¼N/A p¼N/A
P04117/ Fabp4 Fatty acid-binding protein, adipocyte 1.707 (F4)* e 1.3 * e
FABP4_MOUSE p¼0.05442 p¼0.2302
P20491/ Fcer1g High afﬁnity immunoglobulin epsilon receptor subunit gamma 1.048 b 2.552 a
FCERG_MOUSE p¼N/A p¼0.0044
Q8VCF0/ Mavs Mitochondrial antiviral-signaling protein 1.837 b 2.177 b
MAVS_MOUSE p¼N/A p¼N/A
Glycolysis
P17710/ Hk1 Hexokinase-1 1.718 a 1.52 a
HXK1_MOUSE p¼0.004512 p¼0.02119
Q3TRM8/ Hk3 Hexokinase-3 3.299 a 1.857 (F3)* d,e
p¼0.0008967 p¼0.06958HXK3_MOUSE
Pyruvate metabolism
P14152/ Mdh1 Malate dehydrogenase, cytoplasmic 2.938 (F6) 1.118 (F6)* d,e
MDHC_MOUSE p¼ 0.0025 p¼0.561
P45376/ Akr1b1 Aldose reductase 1.857 a 1.311 a
ALDR_MOUSE p¼0.01542 p¼0.0202
TCA cycle
Q8BH04/ Pck2 Phosphoenolpyruvate carboxykinase, mitochondrial 0.967 * e 1.584 a
PCKGM_MOUSE p¼0.6243 p¼0.02746
Q9CPQ1/ Cox6c Cytochrome c oxidase subunit 6C 0.378 a 0.701 c
COX6C_MOUSE p¼0.0000206 p¼ —
Q9CQ75/ Ndufa2 NADH dehydrogenase 1 alpha subcomplex subunit 2 0.564 a 0.693 a
NDUA2_MOUSE p¼0.0006703 p¼0.03969
Q62425/ Ndufa4 Cytochrome c oxidase subunit NDUFA4 0.545 a 0.799 a
NDUA4_MOUSE p¼0.0001127 p¼0.005061
Fatty acid metabolism
Q99JY0/ Hadhb Trifunctional enzyme subunit beta, mitochondrial 0.586 a 0.215 a
ECHB_MOUSE p¼0.002993 p¼0.04001
Q8QZT1/ Acat1 Acetyl-CoA acetyltransferase, mitochondrial 0.552 a 0.533 a
THIL_MOUSE p¼0.0000293 p¼0.0000243
Q8BH95/ Echs1 Enoyl-CoA hydratase, mitochondrial 0.547 a 0.558 a
ECHM_MOUSE p¼0.0004425 p¼0.000000162
Insuline signaling
P35821/ Ptpn1 Tyrosine-protein phosphatase non-receptor type 1 1.471 a 2.196 a
p¼0.02174 p¼0.001486PTN1_MOUSE
Phospholipase
Q8BG07/ Pld4 Phospholipase D4 1.984 a 2.369 a
PLD4_MOUSE p¼0.006469 p¼0.004143
Oxidation-reduction process and response to H2O2
P62715/ Ppp2cb Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform 1.931 (F6) d 1.427 a
PP2AA_MOUSE p¼ 0.0462 p¼0.006338
P08228/ Sod1 Superoxide dismutase [Cu–Zn] 1.939 a 1.281(F1)* e
SODC_MOUSE p¼0.03721 p¼0.06717
O08709/ Prdx6 Peroxiredoxin-6 1.811 a 1.689 a
PRDX6_MOUSE p¼0.01335 p¼0.0002667
Transcription
Q99N69/ Lpxn Leupaxin 2.148 a 1.505* e
LPXN_MOUSE p¼0.04064 p¼0.2182
Q6A068/ CDC5L_MOUSE Cdc5l Cell division cycle 5-like protein 1.9 c 2.021 a
p¼ — p¼ 0.001067
Q9CWL8/ Ctnnbl1 Beta-catenin-like protein 1 2.431 a 1.755 a
CTBL1_MOUSE p¼ 0.01294 p¼ 0.04733
RNA splicing
Q61656/ Ddx5 Probable ATP-dependent RNA helicase DDX5 1.784 (F6) d 1.708 (F6) d
DDX5_MOUSE p¼0.0705 p¼0.0709
Q922V4/ Plrg1 Pleiotropic regulator 1 1.687 a 2.074 a
PLRG1_MOUSE p¼0.01822 p¼0.03083
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Table 1 (continued )
UniProt Acc Gene Name Protein name Fold-Change treated Fold-Change treated
6 hf 12 hf
Q8R149/ Bud13 BUD13 homolog 2.475 b 1.916 b
BUD13_MOUSE p¼N/A p¼N/A
Q9QYS9/ Qki Protein quaking 1.907 b 1.853 b
QKI_MOUSE p¼N/A p¼N/A
Ribosome and ribosome biogenesis
Q99N95/ Mrpl3 39S ribosomal protein L3, mitochondrial 0.495 a 0.509 a
RM03_MOUSE p¼0.00000436 p¼0.00000175
Intracellular protein transport
Q9JKC8/ Ap3m1 AP-3 complex subunit mu-1 0.532 b 0.377 b
p¼N/A p¼N/AAP3M1_MOUSE
Protein folding and degradation
O70591/ Pfdn2 Prefoldin subunit 2 1.605 a 1.517 a
PFD2_MOUSE p¼0.01261 p¼0.02322
P61082/ Ube2m NEDD8-conjugating enzyme Ubc12 2.066 a 1.675 *
p¼0.001301 p¼0.1142UBC12_MOUSE
Q922Y1/ Ubxn1 UBX domain-containing protein 1 2.208 c 1.783 a
UBXN1_MOUSE p¼ — p¼0.01412
P97821/ Ctsc Dipeptidyl peptidase 1 2.123 a 2.056 a
CATC_MOUSE p¼0.001438 p¼0.004243
Cell adhesion and actin cytosqueleton
P27870/ Vav1 Proto-oncogene vav 3.09 b 3.237 b
VAV_MOUSE p¼N/A p¼N/A
Q9JKK7/ Tmod2 Tropomodulin-2 0.413 a 0.626 a
TMOD2_MOUSE p¼0.01508 p¼0.04263
P47226/ Tes Testin 1.883 a 1.457 *
TES_MOUSE p¼0.04618 p¼0.1128
Maintenance of mitocondrial structure
Q8CAQ8/ Immt MICOS complex subunit Mic60 0.383 a 0.519 a
p¼0.003721 p¼0.005439IMMT_MOUSE
a Fold changes in bold and underlined were assigned by MASCOT as a statistically signiﬁcant change considering three or more identiﬁed peptides, the normality test was
successful, and their corresponding p values lower than 0.05.
b Fold changes in bold and underline with a p¼N/A means a statistically signiﬁcant fold changes that the quantitation is supported only by one or two peptides. The p
value was not assigned because the individual peptide are contained in OFFGEL fractions that do not have a normal distribution. If the fold change value is not written in bold
and underlined means it does not pass the normality test of MASCOT.
c Fold changes with a non-calculated p value (p¼ —) were those that did not follow a normal distribution and all the individual peptides supporting the quantiﬁcation
are contained in fractions that do not satisﬁed the normal distributions.
d Fold changes written in italics and followed by a parenthesis indicating a fraction number (F1–F12), indicates proteins that did not pass the normality test of MASCOT
but the p value was calculated based on the detection of one derived peptide in one OFFGEL fraction that has a normal distribution.
e Fold changes labeled with asterisks are those with p values higher than 0.05.
f Statistically signiﬁcant up- and down-regulated proteins were considered those with fold change values lower than 0.60 and higher 1.50, respectively for which
MASCOT assigned a p value lower than 0.05.
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3.1. A233 treatment increases superoxide anion levels in J774.2 cells
Peptide treatment increases •−O2 (superoxide anion) levels in ti-
lapia head–kidney leukocyte cultures [2]. Together, the GO biological
process and the molecular function enrichment analyses indicate an
impact on oxidation–reduction processes after 6 h of treatment, with
the differential up-regulation of superoxide dismutase Sod1 and
Prdx6 peroxidase (Fig. 1, Supplemental Table 2). Prdx6 is primarily a
phospholipid peroxidase that protects membranes from oxidation
and is considered to be a cytoprotective enzyme; it also contains
phospholipase A2 activity required for the activation of NADPH oxi-
dase NOX2, and thus for ROS generation [20,21].
Activated M1 macrophages mediate their cytotoxic and pro-
inﬂammatory effects by producing ROS and RNS such as •−O2 and
NO (nitric oxide), respectively [22]. ROS generation induces cell
damage, for example, by reacting with NO to yield ONOO (per-
oxynitrite anion) [23]. Sod1 and Prdx6 up-regulation might then
suggest an increase in ROS production, while avoiding associated
oxidative stress damage. Correspondingly, the effect of the GHS
A233 and GHRP-6 on •−O2 production was determined, demon-
strating a signiﬁcant increase of •−O2 levels compared with the
control in both cases (Fig. 2). Therefore, A233 treatment might
potentiate macrophage activation and cytotoxic functions, as ROSproduction has been reported to have role in macrophage differ-
entiation [24].3.2. A233 treatment differentially modulates DNA repair and apop-
tosis related proteins
Activated macrophages are protected against ROS induced
oxidative damage by showing, for instance, an enhancement of
DNA repair and resistance to apoptosis [25]. Apoptosis is an or-
dered cascade of enzymatic events that culminates in cell death
and the cleavage of DNA into characteristic nucleosomal frag-
ments. Since peptide treatment increases •−O2 levels, we in-
vestigated the modulation of these events. The GO biological
process enrichment analysis highlighted the differential up-reg-
ulation of DNA repair proteins at 6 and/or 12 h post-treatment
(Fig. 1, Supplemental Table 2). For example, the differentially
modulated protein Nabp1 is a component of the SOSS complex
required for efﬁcient homologous recombination-dependent re-
pair of double-strand breaks and ATM-dependent signaling path-
ways [26,27]. Therefore, these ﬁndings indicate that DNA repair
enhancement and resistance to apoptosis in J774.2 cells might be
potentiated by A233 peptide treatment, which might promote
survival under conditions with high-ROS levels.
Fig. 1. GO biological process and KEGG pathway enrichment analyses of the differentially modulated proteins at 6 and/ or 12 h of treatment with A233 peptide.
Fig. 2. Superoxide anion production in macrophage J774 cells stimulated with
A233 peptide. Cells were incubated with the A233 and GHRP-6 peptides for 4 h at
37 °C in 5% CO2; control cells were treated with Hanks' solution (pH 7.4). Data are
expressed as the absorbance at 620 nm. Statistical signiﬁcance between groups was
determined using one-way ANOVA with Newman–Keuls's test (*: po0.05). The
results are representative of two independent experiments.
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The activation of the transcription factors NF-κB, STAT1 and AP-
1 by stimuli like LPS, and/or IFN-α/β/γ induces the expression ofinﬂammatory and microbicidal M1 genes. To investigate their ac-
tivation in the A233 peptide-stimulated cells, we conducted a TFBS
enrichment analysis at 6 and 12 h post-treatment and at each time
separately. Noticeably, we detected a signiﬁcant enrichment of the
STAT1 targets at 6 and/or 12 h post-treatment, including Eef1g,
Fabp4, Hadhb, Hk3, yar, Mcm3, Phb, Ptcd3,and Rtn3 (Supplemental
Table 2).
In particular, the differentially up-regulated protein Fabp4
(Fig. 1, Table 1) is a target gene of the STAT1 transcription factor
(Supplemental Table 2). The expression of Fabp4 in macrophages is
induced by a pro-inﬂammatory environment, and its decrease
reduces NF-κB activation and the levels of the inﬂammatory cy-
tokines Cox2 and iNOS [29,30]. This protein also displays an an-
tioxidant activity against H2O2 in vitro [31]. The increase in Fabp4
protein may thus link peptide treatment with the establishment of
a pro-inﬂammatory phenotype by responding to STAT1 and in-
ducing NF-κB activation.
3.4. A233 treatment increases IFN-γ levels and induces an antiviral
response
As suggested by the TFBS enrichment analysis, the A233 pep-
tide may activate the STAT1 signaling pathway. IFN-γ polarizes
macrophages to an M1 state through STAT1 activation, while de-
letion of STAT1 compromises viral immunity [32]. Activated STAT1
Fig. 3. IFN-γ production in mouse splenocytes stimulated with A233 peptide
(10 nM). The levels of IFN-γ were measured by ELISA in the cell supernatant after
four days of stimulation. The GHRP-6 and [D-Lys3]-GHRP-6 were included as po-
sitive and negative peptide controls, respectively. Data represent mean7standard
error of the mean (SEM); N¼5. Statisitical analysis was performed by a one-way
analysis of variance, using Newman–Keuls post-test. (*: po0.05). The results are
representative of two independent experiments.
Fig. 4. DENV load in mouse brain after treatment with A233 peptide and virus
challenge. DENV was detected in brain samples collected 7 days after challenge of
treated mice by direct quantiﬁcation on Vero cells. Data represent mean7standard
error of the mean (SEM); N¼7. Statistical analysis was performed by one-way
analysis of variance, using Kruskal–Wallis and Dunn multiple comparison test. (*:
po0.05). The results are representative of two independent experiments.
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ROS-generating enzymes, iNOS and pro-inﬂammatory cytokines
[33]. Therefore, we measured IFN-γ levels in mouse splenocytes
stimulated with the peptide. As suspected, A233 treatment sig-
niﬁcantly increased IFN-γ levels (5099.73786.16 pg/mL) com-
pared to the control cells (558.05726.48 pg/mL). Also, the sti-
mulation with the antagonist peptide [D-Lys3]-GHRP6 induced a
low cytokine secretion (430.4577.22 pg/mL) (Fig. 3).
Considering that this cytokine is a mediator of antiviral activity
against DENV [34], we evaluated the antiviral capacity of A233
peptide in a mouse model of DENV infection. This model, based on
the intracranial inoculation of high viral doses of mouse-adapted
strains, has previously been used to evaluate the efﬁcacy of antiviral
drugs against DENV [35,36]. Our results reveal a signiﬁcant reduc-
tion in viral load in treated mice after intracranial challenge with
DENV-3 (161.43729.71 pfu/mL), compared with the control group
(714.29734.87 pfu/mL) (Fig. 4). A similar outcome was observed
after challenge with the DENV-2 NGC strain (data not shown). The
administration of an antagonist [D-Lys3]-GHRP-6 peptide did not
reduce viral load after challenge (765.71757.54 pfu/mL) (Fig. 4).
Further experiments could be conducted in mice and non-human
primates to evaluate the efﬁcacy of the molecule against infectious
and non-infectious diseases.
On the other hand, peptide treatment of J774.2 cellsdifferentially up-regulates the peroxisomal and mitochondrial
protein MAVS required for innate immune defense against viruses
(Fig. 1, Table 1). The mitochondrial isoform of MAVS activates an
IFN-dependent signaling pathway that ampliﬁes and stabilizes the
antiviral response through the expression of type I IFNs and of
other antiviral cytokines [37]. The differential up-regulation of
MAVS, the increase in IFN-γ levels, and the protection against
DENV infection indicates an anti-viral effect of A233 peptide
treatment. Other mouse model studies examining mechanisms of
antiviral innate immunity against DENV reveal an essential role for
MAVS [38] and IRF-3/7 [39].4. Conclusion
The present study shows that A233 peptide treatment stimu-
lates •−O2 and IFN-γ production in mouse J774.2 macrophages and
splenocytes, respectively. IFN-γ can polarize macrophages to the
M1 classically active state. The proteomic proﬁling of J774.2 cells
stimulated with the A233 peptide indicated an up-regulation of
glycolytic pathway proteins and the down-regulation of fatty acid
beta-oxidation and oxidative phosphorylation proteins, which may
correspond to a shift from aerobic to anaerobic glucose catabolism.
It also suggested the adaptation of J774.2 cells to the increase of
•−O2 levels through the up-regulation of antioxidant enzymes and
of double-stranded DNA break repair proteins and the down-
regulation of the pro-apoptotic protein Bax. In addition, it pointed
to the induction of an antiviral state reﬂected by increased IFN-γ
levels in mouse splenocytes and the differential modulation of
MAVS protein. This effect was assessed in a mouse model of in-
tracranial dengue virus infection, and the A233 peptide was shown
to decrease viral load after challenge. Altogether, peptide treat-
ment may positively regulate pathogen killing by macrophages,
which is supported at the molecular level by the increase in •−O2
and IFN-γ. Further studies should be performed to further test and
extend these ﬁndings.
The iTRAQ data shown in our manuscript should be considered
as preliminary results that should be further validated by addi-
tional proteomics experiments with greater statistical power as
well as by using orthogonal techniques such as western-blotting or
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